Figure 2.

Effect of pharmacological agents that influence natriuretic peptide and 3,5-cyclic guanosine monophosphate (cGMP) signalling. Constructs were cultured under free-swelling conditions with 0 or 10 ng/ml IL-1β and/or 100 nM C-type natriuretic peptide (CNP) or 1H-(1,2,4)oxadiazolo-(4, 3-a)quinoxalin-1-one ODQ (5 μM), P19 (0.5 μM) and cANF4-23 (1 μM) on nitric oxide (NO) release (A), prostaglandin E2 (PGE2) production (B), glycosaminoglycan (GAG) synthesis (C) and total 3,5-cyclic guanosine monophosphate (cGMP) content (D) for 48 hours (n = 9 to 25). Asterisks indicate significant comparisons between untreated control samples with IL-1β and/or IL-1 + CNP and/or IL-1β + CNP + cANF4-23 and/or IL-1β + CNP + P19. All other comparisons (not indicated) were not significant.

Peake et al. Arthritis Research & Therapy 2013 15:R76   doi:10.1186/ar4253
Download authors' original image